🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Clinical Trials in the EU / 2026-525244-14-00
Authorised Phase I

Clinical study to evaluate the safety and efficacy of a new targeted radioactive drug treatment for advanced prostate cancer

2026-525244-14-00 · tracked via the Priya Life Science EU tracker
Sponsor
Fondazione IRCCS Istituto Nazionale Dei Tumori
Sponsor type
Hospital/Clinic/Other health care facility
Therapeutic area
Neoplasms
Decision date
15/09/2026
Enrollment target
5
Sites
Italy

Condition studied

Metastatic prostate cancer

Eligibility

Age group
65+ years, 18-64 years
Sex
Male
Official registry record

This page summarises publicly available CTIS data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View 2026-525244-14-00 on CTIS ↗ ← All trials in the EU